Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FDA approves vemurafenib for treatment of metastatic melanoma.

Oncology (Williston Park, N.Y.) - 1 Sept 2011

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Approval
Share to Indoles
Share to Melanoma
Share to Neoplasm Metastasis
Share to Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Sulfonamides

Share to United States Food and Drug Administration

Share to Vemurafenib

Source

Identifiers

PMID: 22010387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FDA approves vemurafenib for treatment of metastatic melanoma.PMID 22010387Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity Read ↗

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: the first drug approved for BRAF-mutant cancer.Semantic proximity Read ↗

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.Semantic proximity Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.